Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154

Marcus D. Säemann, Maximilian Zeyda, Christos Diakos, Andreas Szekeres, Georg A. Böhmig, Peter Kelemen, Ornella Parolini, Hannes Stockinger, Eva E. Prieschl, Thomas M. Stulnig, Thomas Baumruker, Gerhard J. Zlabinger

Risultato della ricerca: Contributo in rivistaArticolo in rivista

31 Citazioni (Scopus)


BACKGROUND: Therapeutic targeting of Janus kinase 3 (JAK3) has received particular attention, because it is associated with the common gamma signaling of cytokine receptors and thus vitally influences T-cell growth and survival. Recent evidence, however, indicates a critical role for JAK3 in signaling linked to the T-cell antigen receptor. METHODS: In this study we investigated whether targeting JAK3 with a rationally designed inhibitor affects early T-cell activation events. T cells were stimulated by CD3 and CD28 cross-linking, and interleukin (IL)-2 production, activation marker expression, increase of free intracellular Ca2+ concentration, activation of the extracellular-related kinase, and nuclear translocation of transcription factors were evaluated. RESULTS: We found that JAK3 inhibitor treatment dramatically impaired T-cell-receptor (TCR)-induced IL-2 production, surface activation marker expression (CD69, CD154), and homotypic T-cell aggregation. Accordingly, mRNA production of IL-2, interferon-gamma, and IL-10 was profoundly inhibited. Molecular analysis revealed that TCR-triggered phosphorylation of phospholipase C-gamma1, increase in cytoplasmic Ca2+ concentration, and activation of extracellular-related kinase were markedly reduced by the JAK3 inhibitor, resulting in substantially decreased DNA binding of nuclear factor of activated T cells and alkaline phosphatase-1 and subsequent IL-2 promoter activation. Remarkably, on TCR-independent stimulation, IL-2 production, CD69 expression, and blast formation were completely insensitive to JAK3 inhibitor treatment. CONCLUSION: These data indicate that pharmacologic targeting of JAK3 uncouples early TCR-triggered signaling from essential downstream events, which may have important implications for the use of such compounds in T-cell-mediated disorders such as allograft rejection or graft-versus-host disease.
Lingua originaleEnglish
pagine (da-a)1864-1872
Numero di pagine9
Stato di pubblicazionePubblicato - 2003


  • Alkaline Phosphatase
  • Cell Aggregation
  • DNA-Binding Proteins
  • Enzyme Inhibitors
  • Gene Expression
  • Graft Rejection
  • Humans
  • Interleukin-2
  • Janus Kinase 3
  • Jurkat Cells
  • Lymphocyte Activation
  • NFATC Transcription Factors
  • Nuclear Proteins
  • Phosphorylation
  • Promoter Regions, Genetic
  • Protein-Tyrosine Kinases
  • Quinazolines
  • Receptors, Antigen, T-Cell
  • Signal Transduction
  • T-Lymphocytes
  • Transcription Factors
  • Transcription, Genetic
  • Tyrosine


Entra nei temi di ricerca di 'Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154'. Insieme formano una fingerprint unica.

Cita questo